carbinoxamine maleate 0.8 MG/ML Oral Solution

What the CMS Formulary Data Shows for carbinoxamine maleate 0.8 MG/ML Oral Solution

Per the CMS 2026 Part D formulary file, carbinoxamine maleate 0.8 MG/ML Oral Solution (RxNorm concept RXCUI 1010696, generic name carbinoxamine maleate) appears on 20 distinct formulary files spanning 828 Medicare Part D plan offerings - 16.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.3.

Real-world access to carbinoxamine maleate 0.8 MG/ML Oral Solution depends on utilization management as much as tier placement: 75% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,400 Part D beneficiaries filled carbinoxamine maleate 0.8 MG/ML Oral Solution in 2023, with total plan-and-beneficiary spending of $921,020 and an average per-beneficiary annual cost of $657.87. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry carbinoxamine maleate 0.8 MG/ML Oral Solution today.